What are peptides, and why are they suddenly all over our feeds? Peptides are short chains of amino acids, the same building blocks that make up proteins, and our bodies make thousands of them every day. Lately the word has become a wellness buzzword. Then, on October 30, 2026, the U.S. Department of Health and Human Services (HHS) published a new policy about six specific peptides, and the headlines made it sound like a green light. The real picture is narrower and more cautious, so we’ve laid out what the rule says, what it leaves untouched and what we’d want to ask before anyone considers one of these products.

Key takeaways

  • Peptides are short chains of amino acids. Some are well-studied, FDA-approved medicines, like insulin and the GLP-1 drugs used for diabetes and weight management.
  • The new HHS policy covers six peptides: BPC-157, TB-500, epitalon, semax, KPV and MOTS-c. None of them is FDA approved.
  • The policy says HHS doesn’t intend to take enforcement action against licensed pharmacies and physicians who compound these peptides under strict conditions, including a valid patient-specific prescription.
  • The policy is a draft and interim. It doesn’t count as FDA approval, it doesn’t add the peptides to the official list of bulk ingredients pharmacies may compound with, and HHS says it can revisit it if safety problems show up.
  • FDA reviewers recommended against adding each of these six peptides to that list, citing very limited human safety data.
  • “Research use only” peptides sold online are still outside this policy. The policy was written partly to steer people away from them.

What are peptides?

Short chain of soft sage and sand ceramic beads on linen, suggesting amino acids linked as a peptide

In plain terms, a peptide is a short string of amino acids linked together. The National Human Genome Research Institute defines a peptide as a short chain of amino acids, typically 2 to 50, linked by peptide bonds. Longer chains fold into proteins.

Our bodies use peptides as messengers all the time. Many hormones are peptides, including insulin, which helps move sugar from the blood into cells, and oxytocin, which plays a role in labor and breastfeeding. Because peptides can act on specific targets in the body, drug developers have been interested in them for decades. A 2022 review in Signal Transduction and Targeted Therapy notes that more than 80 peptide drugs have been approved worldwide since insulin was first made in 1921.

The catch is that “peptide” describes a type of molecule, much like “protein” or “fat” does. Saying something is a peptide tells us nothing about whether it’s safe, whether it works or how well it was made.

FDA-approved peptide medicines vs. compounded and “research” peptides

Unlabeled amber glass vials and a ceramic mortar on a wooden tray in soft natural light, suggesting pharmacy compounding

Peptide talk often mixes up three very different groups of products.

1. FDA-approved peptide drugs

These have gone through clinical trials and FDA review for safety, effectiveness and manufacturing quality. Insulin and the GLP-1 medicines, such as semaglutide, are the best-known examples. They’re prescribed for specific conditions, and their labels list known risks and side effects.

2. Compounded peptides

Compounding is when a licensed pharmacist or physician combines or alters ingredients to make a medicine for an individual patient. The FDA is clear on the key point: compounded drugs aren’t FDA approved, which means the agency doesn’t review their safety, effectiveness or quality before they’re sold. Compounding has real uses, such as making a version of a drug without an allergen.

3. “Research use only” peptides

This is the gray market. Many peptides are sold online labeled “for research use only” or “not for human consumption,” often shipped from overseas suppliers. These products aren’t approved for people, and there’s no reliable way for a shopper to know what’s in the vial, how pure it is or whether it’s contaminated. The HHS policy itself says it aims to discourage the widespread use of research-use-only peptides from foreign manufacturers, which it describes as a safety risk to U.S. patients.

The FDA has warned about a similar problem with unapproved and compounded versions of GLP-1 weight-loss drugs, including reports of dosing errors with compounded versions and counterfeit products. It’s a helpful reminder that even familiar peptides can cause harm when quality and dosing aren’t controlled.

What the new HHS peptide rule changes

The document is called the “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” HHS announced it in the Federal Register on October 30, 2026, and described it as a draft, interim policy.

Normally, a 503A compounding pharmacy (the traditional, patient-by-patient kind) can only use certain bulk ingredients, mainly components of approved drugs, ingredients with an official USP monograph or substances on what’s called the 503A bulks list. These six peptides don’t fit those categories. Under the new policy, HHS says it doesn’t intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds them, as long as a long list of conditions is met. Those conditions include:

  • A valid, patient-specific prescription. These are prescription-only compounded products under the policy.
  • Only the listed forms and routes. Each peptide is limited to certain forms, such as injection under the skin or into a muscle, a nasal spray, a topical or an oral form.
  • Tested ingredients from registered facilities. The bulk peptide has to come from an FDA-registered facility with a certificate of analysis testing identity, purity, potency, endotoxins, heavy metals, microbes and impurities.
  • One active ingredient per product. No peptide “stacks” or blends.
  • Proof for oral versions. Oral products need documented evidence that the peptide is absorbed in humans. The policy notes that getting peptides absorbed by mouth is inherently difficult.
  • Approved syringes only. Any device used must be an FDA-cleared syringe.
  • Safety reporting. Serious side effects and quality problems must be reported to the FDA’s MedWatch program and to state authorities.
  • Clear labeling. Products must be labeled as compounded drugs that aren’t for resale.

HHS’s stated reasoning is that a controlled, prescription-based option is safer than people buying unregulated products online. HHS also cites newer testing data, patterns of use and its advisory committee’s recommendations.

What the new HHS rule doesn’t change

  • It isn’t FDA approval. None of the six peptides has been approved by the FDA for any use. Their safety and effectiveness haven’t been established through the usual review process.
  • It doesn’t put them on the official bulks list. The policy is a temporary decision not to enforce certain rules while the FDA works through formal rulemaking. That future rulemaking may or may not add these peptides.
  • It’s not permanent. HHS calls it an interim policy that doesn’t create rights for anyone and isn’t binding. It says it may revisit the policy if a safety signal or product quality issue appears.
  • It doesn’t cover online “research” peptides. Buying vials labeled for research use is outside this policy entirely.
  • It doesn’t settle the science. The FDA’s own reviewers concluded that each of these peptides should not be added to the bulks list, largely because human data are so limited.

At a July 2026 meeting of the FDA’s Pharmacy Compounding Advisory Committee, FDA staff presented their reviews of these peptides. For every one of the six, the FDA’s drug center recommended against listing, while the outside advisory committee voted in favor. HHS sided with the committee for this interim policy. That split shows how unsettled the evidence still is.

The policy was also released as a draft with a short public comment window. The Federal Register notice says written comments can be submitted for 2 weeks after publication (through about November 13, 2026) at regulations.gov, under docket HHS-OASH-2026-0496. Details could change.

The six peptides, briefly

We’re sharing what each peptide is and what the FDA found when it reviewed it. We aren’t including doses or protocols, because there’s no FDA-reviewed basis for them, and nothing here is a recommendation to use any of these.

BPC-157

BPC-157 is a lab-made peptide based on a fragment of a protein found in human gastric juice. It’s popular in fitness and injury-recovery circles. The FDA’s review found insufficient clinical safety information and no studies giving it to humans by the oral, injected, nasal or transdermal routes that were proposed. Animal studies raised possible concerns involving blood clotting and the liver, and the FDA flagged a risk of immune reactions. A 2025 systematic review found 36 studies on BPC-157, but only one was a clinical study in people, and the authors reported finding no clinical safety data. The policy allows injected, oral and topical forms.

TB-500

TB-500 is a synthetic seven-amino-acid fragment of thymosin beta-4, a protein involved in cell movement and tissue repair. The FDA reviewed it for wound healing and found a lack of clinical and nonclinical safety information. It said potential risks in humans are unknown, including immune reactions. The policy allows injection under the skin or into a muscle.

Epitalon

Epitalon is a synthetic four-amino-acid peptide often marketed for “longevity” and sleep. The FDA reviewed it for insomnia and found a lack of evidence that it works for that use, a lack of human safety data and possible immune-reaction concerns. The policy allows injections given in intermittent courses.

Semax

Semax is a peptide registered as a nasal drug in Russia and marketed online for focus and brain health. The FDA reviewed it for stroke-related brain injury, migraine and nerve pain. It found insufficient evidence of effectiveness, insufficiently characterized safety data and unanswered questions about how a nasal spray product would be designed and tested. The policy allows nasal use only.

KPV

KPV is a three-amino-acid fragment of a hormone called alpha-melanocyte-stimulating hormone. It has been studied in the lab for inflammation and wound healing. The FDA said it didn’t identify clinical studies of KPV in humans and that potential safety risks are unknown. The policy allows topical and oral forms.

MOTS-c

MOTS-c is a peptide encoded by the DNA in our mitochondria, the energy-producing parts of our cells, and it’s marketed for metabolism and weight. The FDA reviewed it for obesity and osteoporosis and found no information on its use in humans and a lack of evidence that it works for those conditions. The policy allows injection under the skin or into a muscle.

The pattern is consistent: interesting lab and animal research, very little careful testing in people.

Peptides for women: what we’d want to know

Many of the ads and videos about peptides for women are aimed at us in our 40s, 50s and beyond, promising help with menopause, energy, weight, joints, skin or sleep. Still, none of the six peptides in this policy has been tested in well-designed studies for menopause symptoms, and the FDA reviews found little or no human data for most of them.

There are well-studied options for many of these concerns, and a clinician can help sort them out. Our menopause symptoms guide and perimenopause symptoms guide walk through what’s typical and when to get checked, and our guide on how to balance hormones naturally covers the everyday habits with the strongest evidence. For muscle and joint health as we age, regular strength training for women over 40 has far more research behind it than any of these peptides.

Topical peptide skincare vs. injectable peptides

Frosted dropper bottle with clear serum drops on pale stone beside a sage leaf, suggesting topical peptide skincare

Search interest in peptide serums has climbed fast, and a peptide in a face cream is a very different product from an injectable one.

Skincare peptides are usually sold as cosmetics. Under FDA rules, a product meant to improve appearance is generally a cosmetic, while a product meant to treat a condition or change how the body works is generally regulated as a drug. Cosmetics don’t need FDA approval before they’re sold, and they’re applied to the skin surface rather than injected.

Some topical peptides have been studied in small controlled trials. For example, a 12-week study of 93 women found that a moisturizer containing a palmitoyl pentapeptide improved the look of fine lines more than the same moisturizer without it. A systematic review of topical peptides for aging skin found some encouraging results, but also noted that many products lack well-designed studies and that we know little about how well these peptides penetrate skin. In short, peptide serums may offer modest cosmetic benefits, and they’re a low-risk category compared with injections. The new HHS policy doesn’t apply to them.

Safety questions to ask before considering any peptide

Open blank notebook with pencil and herbal tea on linen in soft morning light, suggesting questions to ask a clinician

If a clinician brings up a compounded peptide, or you’re seeing them promoted by a clinic or telehealth service, these questions can help you get clearer answers:

  • Is this an FDA-approved medicine, or is it compounded? If it’s compounded, why is an approved option not a good fit for me?
  • What condition is this meant to treat, and what human evidence supports it for that condition?
  • Which pharmacy will compound it, is it state-licensed, and can it show a certificate of analysis for the ingredient?
  • Is this one of the six peptides in the HHS policy, and does the form match what the policy allows?
  • What side effects should I watch for, and who do I call if something feels off?
  • How does this interact with my other medicines, supplements or health conditions?

A few red flags are worth walking away from: products labeled “for research use only,” sellers who don’t require a prescription, blends of several peptides in one vial, promises that sound too good to be true and anyone who discourages you from talking to your regular doctor. If you do have a side effect from any drug or compounded product, you or your clinician can report it to the FDA’s MedWatch program.

When to see a clinician, and who should be extra careful

We’d suggest talking with a doctor, nurse practitioner or pharmacist before trying any peptide product beyond a cosmetic skincare item, and especially if you:

  • Are pregnant, trying to conceive or breastfeeding. There’s essentially no safety data for these peptides in pregnancy.
  • Have a history of cancer or a strong family history of it, since the long-term effects of peptides promoted for growth and tissue repair haven’t been studied.
  • Have a bleeding disorder or take blood thinners, given the FDA’s notes on possible clotting-related signals in animal studies of BPC-157.
  • Have an autoimmune condition, allergies or a history of reactions to injections.
  • Have liver or kidney disease, diabetes or heart disease.
  • Are considering peptides for menopause, weight, sleep or mood, since there are proven treatments a clinician can review with you.

Get medical care right away for signs of a serious reaction, such as trouble breathing, swelling of the face or throat, chest pain, a fast heartbeat, severe pain, redness or warmth at an injection site, or a fever.

FAQ

What are peptides in simple terms?

Peptides are short chains of amino acids. They’re smaller than proteins, and our bodies use many of them as signals and hormones. Some peptides are approved medicines, while others are experimental compounds with little human research.

Did HHS approve BPC-157 and the other peptides?

No. HHS announced that it doesn’t intend to take enforcement action against licensed pharmacies and physicians compounding six peptides under specific conditions. None of the six is FDA approved, and the policy is described as interim and not binding.

Can I buy these peptides online now?

The policy covers compounding by state-licensed pharmacies, federal facilities and licensed physicians with a valid patient-specific prescription. It doesn’t cover “research use only” products sold online, and HHS says it hopes to move people away from those products.

Are peptide serums safe?

Peptide skincare products are generally sold as cosmetics and are applied to the skin, so they’re a different category from injectable peptides. As with any skincare product, patch-testing is a good idea, and anyone with sensitive skin or a skin condition can ask a dermatologist.

Are collagen peptides the same thing?

No. Collagen peptides are broken-down collagen protein sold as a food-based supplement. They’re unrelated to the six peptides in the HHS policy. Supplements have their own rules, and our supplements 101 guide covers how to approach them.

Bottom line

So, what are peptides? They’re short amino acid chains that include some of medicine’s most important drugs and a lot of hyped, barely tested compounds. The new HHS policy opens a narrow, prescription-only path for compounding six of these peptides under strict conditions. It doesn’t approve them, doesn’t make them proven or safe and doesn’t cover the “research” vials sold online. If you’re curious about peptides, the best next step is a conversation with a clinician who knows your health history and can weigh the thin evidence against your goals.

Sources

Want more practical, evidence-based guidance like this? Join the newsletter for new guides as soon as they’re published.

⚕️ Disclaimer: This article is for general education and isn’t medical advice. Talk with a doctor or other qualified healthcare professional about your own health, especially if you’re pregnant, nursing, taking medication, or managing a condition. Read our full medical disclaimer.